The phenotypic screens described in the accompanying Discovery Pipeline proposal do not directly identify the small-molecule target, yet target identification is vitally important to follow-up, medicinal chemistry efforts. Target identification, including both the therapeutic target and """"""""off targets"""""""" that can result in unwanted """"""""side effects"""""""", enables optimization of a compound's selectivity and reduction in the potential for side effects of a resultant drug. Target discovery and validation as it is currently practiced is a significant bottleneck to drug discovery. This proposal offers a solution to the target identification problem through the systematic use of three distinct and interdisciplinary approaches. Proteomic, genetic and computational methodologies have been developed at the Broad Institute and will be implemented as a critical follow-up to screening results. Specifically, we will: 1) develop a systematic, proteomic approach to identify targets that underlie smallmolecule screening discoveries;2) combine small-molecule and RNAi methods to identify or to validate targets that underlie small-molecule screening discoveries;and 3) develop computational methods based on gene expression, small-molecule screening, and proteomic and RNAi data to identify pathways and targets that underlie small-molecule screening discoveries. The problem of target identification is one that may be solved not by a single 'killer'technology;rather, we envision the analytical integration of multiple, complementary approaches. Each of these is dependent upon a focused, interdisciplinary effort to a problem that is unlikely to be solvable with the expertise of one discipline alone. We are proposing to develop small-molecule drugs to alleviate unmet medical needs. In order to maximize a drug's potency and minimize a drug's unwanted side-effects, we need to understand all the proteins (""""""""targets"""""""") that a drug candidate will interact with. This proposal seeks to use a combination of cutting-edge scientific approaches available at the Broad Institute to address the difficult problem of target identification.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Linked Research project Grant (RL1)
Project #
6RL1HG004671-03
Application #
7649572
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Ajay, Ajay
Project Start
2007-09-18
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$1,163,676
Indirect Cost
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Yu, Channing; Mannan, Aristotle M; Yvone, Griselda Metta et al. (2016) High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 34:419-23
Chattopadhyay, Shrikanta; Stewart, Alison L; Mukherjee, Siddhartha et al. (2015) Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Rep :
Chou, Danny Hung-Chieh; Vetere, Amedeo; Choudhary, Amit et al. (2015) Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc 137:7929-34
Krönke, Jan; Udeshi, Namrata D; Narla, Anupama et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343:301-5
Dan?ík, Vlado; Carrel, Hyman; Bodycombe, Nicole E et al. (2014) Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses. J Biomol Screen 19:771-81
Gustafsdottir, Sigrun M; Ljosa, Vebjorn; Sokolnicki, Katherine L et al. (2013) Multiplex cytological profiling assay to measure diverse cellular states. PLoS One 8:e80999
Frumm, Stacey M; Fan, Zi Peng; Ross, Kenneth N et al. (2013) Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol 20:713-25
Schenone, Monica; Dan?ík, Vlado; Wagner, Bridget K et al. (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9:232-40
Mulrooney, Carol A; Lahr, David L; Quintin, Michael J et al. (2013) An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries. J Comput Aided Mol Des 27:455-68
Hartwell, Kimberly A; Miller, Peter G; Mukherjee, Siddhartha et al. (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 9:840-848

Showing the most recent 10 out of 36 publications